Abstract. The aim of the study was to estimate the long-term results and the prognostic value of clinical and pathological factors following R0 anterior resection with total mesorectal excision (TME). Ninety-eight consecutive patients with histologically confirmed rectal cancer were studied prospectively with five-year follow-up. Survival was calculated using the Kaplan-Meier method and differences between curves were tested by the log-rank test. Multivariate analysis was performed using the Cox regression model. Recurrence-free survival (RFS) was 63.6%. Mean time of recurrence was 13.8 months (range 3-38). Local recurrence rate was 7.8% with the mean time of 12.7 months (range 3-25). In univariate analysis Dukes’ stage (RFS for stage: A=93.2%; B=53.8%; C=26.3%) and preoperative CEA serum level (s-CEA) (for s-CEA ≤5 ng/ml RFS=93.8%; for s-CEA >5 ng/ml RFS = 5.9%) significantly influenced survival (P<0.005 and P<0.00001). These parameters were also found to be independent prognostic factors in multivariate analysis (P<0.05 and P<0.00001). Survival was worse in older female patients with low-localised poorly differentiated tumors; however, those variables had not significant impact on prognosis. Neither symptom duration nor mucinous histology was significantly related to survival. Using TME technique a low local recurrence rate resulting in improved survival can be achieved. Apart from clinicopathological staging, elevated s-CEA can identify patients with poor prognosis. In addition to TME adjuvant therapy for this high-risk group should be considered.

Introduction

Cancer of the colon and rectum remains a problem of public health. It is assessed that in the world there are ~1 million new cases and 500,000 cancer-related deaths each year (1).

Materials and methods

Patients. From January 1998 to December 1999 at the Second Department of Surgical Oncology at Lower Silesian Oncology Center 98 consecutive patients with histologically confirmed rectal cancer underwent an anterior resection with sphincter preservation. Seventy-seven of these (75%) entered the study fulfilling the inclusion criteria: primary tumor localised maximally 12 cm from the anal verge, absence of distant metastases (intraoperative examination, chest radiogram, abdominal sonography, CT scanning), lack of intraoperative bowel perforation, absence of macroscopic infiltration of adjacent organs, distal and radial margins microscopically free of cancer infiltration (R0 resection) and lack of liver disorders. All patients underwent elective surgery with preoperative bowel preparation by means of 4 l of polyethylene glycol solution one day before surgery. Prophylactic antibiotics were administered at the anaesthesia induction. Time of the follow-up was five years. The data were prospectively collected.

Surgical treatment. Resection of the rectum was performed according to the TME principles with sharp dissection under...
direct vision of the plane between the parietal and visceral pelvic fascia to the levator level. Special effort was made to identify and preserve the hypogastric plexuses and pelvic nerves. Distal margin of minimum 2 cm was achieved. End to end anastomosis was constructed using double-stapling technique with the Proximate TLH transverse and Proximate ILS circular intraluminal devices (Ethicon Endo-Surgery Europe, Norderstedt, Germany). Bowel lavage was performed using 2% povidone iodine solution.

Adjuvant therapy. Adjuvant therapy was achieved for patients with tumors penetrating beyond the bowel wall (Dukes’ B, n=26) or with lymph node metastases (Dukes’ C, n=19). Staging was established by means of preoperative endorectal ultrasound and confirmed by histological examination of resected specimen. Twenty-eight patients received preoperative five-day radiation 25 Gy (5x5 Gy) and postoperative chemotherapy with 5-fluorouracil and folinic acid. Seventeen patients received adjuvant radiochemotherapy (5-fluorouracil + folinic acid and 50.4 Gy radiation: 25x1.8 Gy + 5.4 Gy boost).

Follow-up. Follow-up was scheduled every three months during the first postoperative year and every six months thereafter. Physical examination, blood tests, serum markers, barium enema, endoscopy, chest radiograph and abdominal ultrasound were performed. In each case where cancer recurrence was suspected more precise investigation using endorectal sonography, computed tomography or radionuclide scanning was performed.

Clinical factors. For each patient gender and age were recorded. Age ranged from 35 to 89 years, mean was 60.7, median was 60. Thus, we stated a level of 60 years as a cut-off point for age analysis. The site of the primary tumor was divided in two groups: >7 cm and ≤7 cm from the anal verge for separate consideration of the intra- and extraperitoneal tumors. Symptom duration (divided into: ≤3 months, 3-6, 6-12, >12 months) was obtained from the patients records. Patients were also classified according to preoperative serum level of carcinoembryonic antigen (s-CEA) with the cut-off value of 5 ng/ml (16). Detailed characteristics of patient subgroups are given in Table I.

Pathological factors. Staging of tumours was evaluated according to Dukes’ criteria. Patients with tumors without mucin secretion were divided into three groups depending on differentiation grade: well-differentiated (G1), moderately (G2) and poorly differentiated (G3). Adenocarcinomas with mucin histology were distinctly evaluated from non-mucinous ones (Table I).

---

**Table I. Impact of clinical and pathological variables on five-year recurrence-free survival.**

<table>
<thead>
<tr>
<th>Patient characteristics</th>
<th>Number (%) of patients</th>
<th>Recurrence-free survival rate</th>
<th>Univariate analysis</th>
<th>Multivariate analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age &lt;60 years</td>
<td>33 (43%)</td>
<td>71.7±8.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age ≥60 years</td>
<td>44 (57%)</td>
<td>56.7±7.5</td>
<td>P=0.209</td>
<td>NS</td>
</tr>
<tr>
<td>Men</td>
<td>43 (56%)</td>
<td>64.5±7.4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Women</td>
<td>34 (44%)</td>
<td>61.0±8.5</td>
<td>P=0.685</td>
<td>NS</td>
</tr>
<tr>
<td>Tumor &gt;7 cm from anal verge</td>
<td>19 (25%)</td>
<td>72.7±10.4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tumor ≤7 cm from anal verge</td>
<td>58 (75%)</td>
<td>60.0±6.5</td>
<td>P=0.249</td>
<td>NS</td>
</tr>
<tr>
<td>Symptom duration &lt;3 months</td>
<td>15 (20%)</td>
<td>66.7±12.2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Symptom duration 3-6 months</td>
<td>17 (22%)</td>
<td>69.3±11.5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Symptom duration 6-12 months</td>
<td>30 (38%)</td>
<td>56.7±9.0</td>
<td>P=0.484</td>
<td>NS</td>
</tr>
<tr>
<td>Symptom duration &gt;12 months</td>
<td>15 (20%)</td>
<td>65.0±12.7</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Preoperative s-CEA ≤5 ng/ml</td>
<td>48 (62%)</td>
<td>93.8±3.5</td>
<td>P&lt;0.00001</td>
<td>P&lt;0.00001</td>
</tr>
<tr>
<td>Preoperative s-CEA &gt;5 ng/ml</td>
<td>29 (38%)</td>
<td>5.9±5.3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dukes’ stage A</td>
<td>32 (41%)</td>
<td>93.2±4.6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dukes’ stage B</td>
<td>26 (34%)</td>
<td>53.8±9.8</td>
<td>P&lt;0.005</td>
<td>P&lt;0.05</td>
</tr>
<tr>
<td>Dukes’ stage C</td>
<td>19 (25%)</td>
<td>26.3±10.1</td>
<td>P&lt;0.0001</td>
<td>P&lt;0.05</td>
</tr>
<tr>
<td>Malignancy grade G1</td>
<td>10 (15%)</td>
<td>78.8±13.4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Malignancy grade G2</td>
<td>31 (46%)</td>
<td>63.7±8.7</td>
<td>P=0.391</td>
<td>NS</td>
</tr>
<tr>
<td>Malignancy grade G3</td>
<td>26 (39%)</td>
<td>57.7±9.7</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-mucinous histology</td>
<td>67 (87%)</td>
<td>63.5±6.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mucinous histology</td>
<td>10 (13%)</td>
<td>60.0±15.5</td>
<td>P=0.843</td>
<td>NS</td>
</tr>
</tbody>
</table>

s-CEA, preoperative serum level of carcinoembryonic antigen; NS, not significant.
Statistical analysis. Data analysis was performed using the software Statistica™ version 5. All clinical and pathological variables were considered in univariate analysis. To examine the impact of individual parameters on long-term outcome, five-year survival analysis was used. Recurrence-free survival (RFS) was calculated according to the Kaplan-Meier method and differences between curves were tested by the log-rank test, using \( P<0.05 \) as the significance limit. Factors significant in univariate analysis were entered into the Cox proportional hazards regression model for multivariate analysis. Using this approach we obtained independent factors on prognosis.

Results

There were no postoperative deaths. Forty-nine patients were still alive without any evidence of recurrent disease after five years of follow-up in each case. Thus, the five-year RFS rate was 63.6% (Kaplan-Meier estimation: 63.0±5.6%). Four patients were alive with systemic dissemination, 24 patients died before the end of follow-up. Mean time of recurrence was 13.8 months (range, 3-38 months). In 6 patients (7.8%) local recurrence developed with the mean time of 12.7 months (range, 3-25 months).

Survival was worse in older (≥60 years) and female patients. In the univariate analysis influence of patient age and sex on prognosis was not significant. Survival following curative resection of cancers localised >7 cm from the anal verge was better than those with lower sites, but site of the primary tumor did not appear to be significantly important in the prediction of outcome. Shorter periods (<3 and 3-6 months) between first symptoms of disease and treatment were related to a better survival, although not significantly different in comparison with symptom duration lasting 6-12 and >12 months. An increased (>5 ng/ml) preoperative s-CEA was of importance in the prediction of poorer prognosis with a very high degree of significance (\( P<0.00001 \), relative risk \( r=13.79 \), 95% CI=4.57-41.66). Differences in survival rates according to Dukes' stage also led to a high degree of statistical significance (\( P<0.00001 \); Dukes' B: P=0.00363, \( r=9.23 \), 95% CI=1.81-30.09; Dukes' C: P=0.00008, \( r=20.1 \), 95% CI=3.00-46.33). Better outcome was observed in patients with well or moderate differentiation of cancer but moderately differentiated tumors sited at the middle-upper rectum. However, the differences were not significant, possibly due to the small sample size. Cerrutini et al. reviewed 801 patients after curative resection and found the worse 10-year overall survival for the youngest (<50 years) and elderly (>70), poorly differentiated cancers and mucinous tumors (7). In our study, apart from the Dukes' stage, only preoperative s-CEA significantly affected RFS survival in univariate analysis.

CEA is a surface-bound tumor-associated antigen discovered by Gold and Freedman (17). It is an intercellular adhesion glycoprotein with a molecular mass of ~180 kDa, belonging to the immunoglobulin superfamily (18). CEA is expressed at low levels in the embryonic and foetal gut, adult colon epithelium and other endodermal tissues (19). Serum CEA may be elevated in smokers, patients with liver diseases and several benign and malignant disorders of the gastrointestinal tract (20). CEA is overexpressed in ~95% of colorectal cancers and differs from normal expression in that it loses its typical apical localisation, is aberrantly glycosylated and actively secreted (21). The main clinical value of s-CEA in the colorectal carcinoma is the early detection of recurrence (22), but its usefulness for the prediction of long-term prognosis is investigated.

Wanebo et al. first reported the relationship between elevated preoperative s-CEA (>5 ng/ml) and higher recurrence rate (23). Similar to our study, more recent studies confirmed the significant impact of s-CEA on patient outcome in multivariate analyses (8,24-29). Our group was too small for effective stratification of the s-CEA importance in Dukes' stages. Results of such stratifications made by other authors are discrepant. Harrison et al. found s-CEA as a significant and independent prognostic factor for lymph node-negative cancers (30), whereas Chen et al. only for stage B tumors (31). In contrast Wang et al. and Bannura et al. noted that higher preoperative s-CEA was related to poorer survival of lymph node-positive patients (32,33). Moertel et al. reported its independent prognostic value only in patients with involvement of four or more lymph nodes (34). Different results were observed in the trial of Gastrointestinal Tumor Study Group: s-CEA affected survival of patients with one to four positive nodes (35). Moreover, Wang et al. in another study concluded that prediction of significant outcomes persisted for patients analysed separately at Astler-Coller stage C1 (lack of tumor penetration beyond the bowel wall) and C2 (presence of penetration) (36).

The cut-off point of s-CEA in our study was 5 ng/ml (the normal range in our laboratory) (16). This approach is in accordance with other investigators (8,27-29,32,33,36). However, the s-CEA is a continuous variable, therefore another level as a cut-off point might be more accurate for its examination of resected specimen; therefore, the exclusion of patients with systemic dissemination or persisted tumor deposits from the study.

In rectal carcinoma an effective prediction of patient outcome is a clinical problem. The significant impact of tumor stage on survival following R0 resection is non-disputable. Many other parameters are extensively investigated but results are more discordant and conflicting. We noted better outcomes for younger and male patients with well or moderately differentiated tumors sited at the middle-upper rectum. However, the differences were not significant, possibly due to the small sample size. Cerrotini et al. reviewed 801 patients after curative resection and found the worse 10-year overall survival for the youngest (<50 years) and elderly (>70), poorly differentiated cancers and mucinous tumors (7). In our study, apart from the Dukes' stage, only preoperative s-CEA significantly affected RFS survival in univariate analysis.

The Cox proportional hazards regression analysis identified preoperative s-CEA as the most important prognostic factor (\( P<0.00001 \), \( r=27.90 \)). Significant impact of Dukes' stage on five-year RFS also persisted in the multivariate analysis (\( P<0.005 \); Dukes' B: \( P=0.0172 \), \( r=6.33 \); Dukes' C: \( P=0.0260 \), \( r=5.63 \)) but was less important than preoperative s-CEA. The results are summarized in Table I.

Discussion

The RFS rate achieved in our patients was high. The main reason seems to be that >40% of patients were in the early stage of disease (Dukes' A). It may be also partially explained by accurate preoperative staging and adequate pathological
Moreover, molecular and genetic investigations are still needed. s-CEA should be stated in further controlled randomized trials. The real benefit from adjuvant therapy in patients with elevated s-CEA may be helpful. One of them is s-CEA, associated with tumor disorganized growth and movement of transformed cells; therefore, surgery alone as the treatment of choice is recommended (39). However, recurrent disease can develop despite TME, even in patients at the earliest stage of disease (40). These high-risk patients may be candidates for adjuvant treatment (41). For the identification of this subset other factors can be helpful. One of them is s-CEA, associated with tumor aggressiveness. In colorectal cancer CEA appears to participate in several cellular functions including intercellular and cell-matrix adhesion, signal transduction and cellular migration suggesting that CEA may have a role in disorganised growth and movement of transformed cells; thus, can facilitate tumor invasion and metastasis (42,43). Therefore, s-CEA is considered a significant, independent and effective prognostic factor recommended for routine clinical application together with stage parameters (44). The real benefit from adjuvant therapy in patients with elevated s-CEA should be stated at further controlled randomized trials. Moreover, molecular and genetic investigations are still needed for better explanation of cancer biology.

References